The Latest Breaking News from NICE

Rangers next Europa League opposition manager bills showdown in France as 'must win'

Nice boss Franck Haise has labelled their Europa League showdown against Rangers this month a must-win game

The National (Scotland) · Nov 8, 2024

Hormone replacement therapy: Experts debunk the eight most common misconceptions

NICE has revised its guidelines on HRT

The Independent UK · Nov 7, 2024

HRT should be the 'first-line' therapy for menopause, new UK guidance confirms

The new guidance comes after a controversial draft last year suggested CBT could be on par with HRT for treating menopause symptoms

Woman & Home · Nov 7, 2024

Hundreds of blood cancer patients to benefit from new Pfizer treatment

Myeloma affects 24,000 people a year in the UK

The Independent UK · Oct 29, 2024

3 Tech Stocks With Massive Analyst Price Target Upsides

The tech market is well-positioned for significant growth thanks to the growing adoption of emerging technologies like AI, ML, cloud computing, and ERP. Therefore, it could be wise to invest in top tech stocks NICE Ltd. (NICE), LiveRamp Holdings (RAMP), and TaskUs (TASK) with massive analyst price target upsides. Read…

StockNews.com · Oct 28, 2024

Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

The Conversation · Oct 28, 2024

Which disease-modifying Alzheimer’s drugs are the most promising?

Many drugs in development aim to delay, slow or reverse symptoms, but which are causing the biggest stir?

The Guardian - UK · Oct 25, 2024

Tens of thousands of UK dementia patients to be enrolled in clinical trials

News of the £20m scheme comes as new drug for Alzheimer’s was rejected for use on NHS in England

The Guardian - UK · Oct 24, 2024

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers

The Independent UK · Oct 23, 2024

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

The Independent UK · Oct 23, 2024